PRMT5 and chronic myelogenous leukemia, BCR-ABL1 positive: Ongoing research into PRMT5 inhibitors may provide novel strategies to counteract its oncogenic effects, offering new avenues for targeted therapies in AML, CML, and other myeloid neoplasms.